Company BioInvent International AB

Equities

BINV

SE0015244520

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for BioInvent International AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe Europe Other stock markets 15:24:11 29/04/2024 BST			5-day change	1st Jan Change
25.32 ^SEK	+0.70%		+10.30%	+35.55%

04-24	BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-03	BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	MT

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Number of employees: 109

SEK in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	326	100.0 %	71	100.0 %	-78.09%

SEK in Million	2022	Weight	2023	Weight	Delta
United States 66.3 %	273	83.8 %	47	66.3 %	-82.66%
Sweden 25.6 %	26	7.9 %	18	25.6 %	-28.75%
Europe 4.1 %	27	8.3 %	3	4.1 %	-89.11%
Other Countries 4.0 %	-	-	3	4.0 %	-

Managers	Title	Age	Since
Martin Welschof CEO	Chief Executive Officer	63	31/08/18
Stefan Ericsson DFI	Director of Finance/CFO	61	31/12/97
Marie Moores COO	Chief Operating Officer	-	31/01/22
Björn Frendéus CTO	Chief Tech/Sci/R&D Officer	51	31/12/00
Andres McAllister CTO	Chief Tech/Sci/R&D Officer	68	31/12/16
Cecilia Hofvander IRC	Investor Relations Contact	-	31/01/21
Emma Meurling HRO	Human Resources Officer	-	-
Ingunn Munch Lindvig LAW	General Counsel	-	11/06/23
Sylvie Ryckebusch PRN	Corporate Officer/Principal	-	08/06/22
Kristoffer Rudenholm Hansson PRN	Corporate Officer/Principal	50	31/12/15

Members of the board	Title	Age	Since
Bernd Seizinger BRD	Director/Board Member	67	31/12/17
Leonard Kruimer CHM	Chairman	66	11/05/16
Vincent Ossipow BRD	Director/Board Member	55	11/05/16
Thomas O. Hecht BRD	Director/Board Member	73	02/07/20
Erik Esveld BRD	Director/Board Member	-	28/04/21
Nanna Liebach Lüneborg BRD	Director/Board Member	49	11/07/22
Kristoffer Bissessar BRD	Director/Board Member	56	31/12/17
Natalie Berner BRD	Director/Board Member	34	11/07/22
Martin Pålsson BRD	Director/Board Member	45	31/12/21
Elin Birgersson BRD	Director/Board Member	39	31/12/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,804,362	57,013,147 ( 86.64 %)	0	86.64 %

Name	Equities	%	Valuation
Redmile Group LLC 15.39 %	10,127,860	15.39 %	16 M kr
Van Herk Investments BV 10.08 %	6,630,965	10.08 %	11 M kr
Forbion Capital Partners Management Holding BV 9.422 %	6,200,285	9.422 %	10 M kr
HBM Partners AG 7.803 %	5,135,000	7.803 %	8 M kr
HBM Partners AG (Investment Management) 7.803 %	5,135,000	7.803 %	8 M kr
Omega Fund Management LLC 6.304 %	4,148,211	6.304 %	7 M kr
Swedbank Robur Fonder AB 1.944 %	1,279,505	1.944 %	2 M kr
Dharminder Singh Chahal 0.4559 %	300,000	0.4559 %	476 964 kr
Erik Penser Bank AB (Invt Mgmt) 0.3649 %	240,132	0.3649 %	381 781 kr
Tanglin Asset Management AB 0.1087 %	71,547	0.1087 %	113 751 kr

BioInvent International AB

The Gamma Building Ideongatan 1

223 70, Lund

+46 4 62 86 85 50

http://www.bioinvent.com

address BioInvent International AB(BINV)

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.15 SEK

Average target price

83 SEK

Spread / Average Target

+230.02%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOINVENT INTERNATIONAL AB	+35.55%	151M
VERTEX PHARMACEUTICALS INCORPORATED	-2.04%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+3.09%	22.15B
BIONTECH SE	-16.16%	21.02B
GENMAB A/S	-8.38%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.89%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.46%	13.68B
SAREPTA THERAPEUTICS, INC.	+34.26%	12.17B

Bio Therapeutic Drugs